The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: a systematic review and meta-analysis of randomized controlled trials

Vali Musazadeh,Kimia Assadian,Fatemeh Rajabi,Amir Hossein Faghfouri,Yosra Soleymani,Zeynab Kavyani,Behnam Najafiyan
DOI: https://doi.org/10.1016/j.phrs.2024.107398
2024-09-04
Abstract:Background: Patients with non-alcoholic fatty liver disease (NAFLD) benefit from using synbiotics. However, findings from existing trials remain contentious. Therefore, this meta-analysis evaluated the effects of synbiotics on liver enzymes, blood pressure, inflammation, and lipid profiles in patients with NAFLD. Methods: We searched PubMed, Embase, Cochrane, Scopus, and Web of Science for randomized controlled trials (RCTs) regarding synbiotics supplementation in patients with NAFLD. Results: The meta-analysis revealed that synbiotics supplementation significantly improved liver enzymes (AST, WMD: -9.12 IU/L; 95% CI: -13.19 to -5.05; ALT, WMD: -8.53 IU/L; 95% CI: -15.07 to -1.99; GGT, WMD: -10.42 IU/L; 95% CI: -15.19 to -5.65), lipid profile (TC, WMD: -7.74mg/dL; 95% CI: -12.56 to -2.92), obesity indices (body weight, WMD: -1.95kg; 95% CI: -3.69 to -0.22; WC, WMD: -1.40cm; 95% CI: -2.71 to -0.10), systolic blood pressure (SBP, WMD: -6.00mmHg; 95% CI: -11.52 to -0.49), and inflammatory markers (CRP, WMD: -0.69mg/L; 95% CI: -1.17 to -0.21; TNF-α, WMD: -14.01pg/mL; 95% CI: -21.81 to -6.20). Conclusion: Overall, supplementation with synbiotics positively improved liver enzymes, obesity indices, and inflammatory cytokines in patients with NAFLD.
What problem does this paper attempt to address?